References

List of Publications

Publications

Mrosowsky, T., Schönermark, M.P., (2017): Gentherapie ante portas - Lösungsansätze für das Erstattungsdilemma. Welt der Krankenversicherung, Ausgabe 10/2017, ISSN: 2193-4479

Read the whole article for free here (German only).

Schönermark, M.P. (2017): Interview mit Herrn Magnus v. Stackelberg, stellvertretender Vorstandsvorsitzender des GKV-Spitzenverbands. HNO, Band 65, Juni 2017: 523-525

During the interview with Prof. Matthias P. Schönermark, Mr. Magnus  von Stackelberg – the deputy Chairman of the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) – took stock for the SHI of the ending legislative period.

Read our blog article.

Dierks, C, Schönermark, M.P. (2016): Patientenregister im deutschem Versorgungskontext als „Auflage“ im Nutzenbewertungsverfahren nach § 35a SGB V PharmR Heft 08/2016: 305-309

Read the whole article for free here (German only).

Schönermark, M.P. (2014): Der unaufhaltsame Siegeszug der Gesundheitsökonomie. HNO, Band 62, März 2014:157-158

Read the whole article at HNO edition 3/2014 (German only).

Schönermark, M.P., Hollander, I., Temme, T. (2013): Herausforderung AMNOG. PharmInd 75, Nr. 12: 1912-1916

Read the whole article at pharmind 2013, No. 12 (German only).

Schönermark, M.P., Franz, S., Graf von der Schulenburg, J.-M., Prenzler, A. (2013): Kostenevaluation von Arzneimitteln: internationale Standards der Gesundheitsökonomie und derzeitige deutsche Praxis. Studie für den Verband der forschenden Arzneimittelhersteller

You can download the complete study here (German only).

Hager, M., Temme, T., Schönermark, M.P. (2012): Germany’s Price Reform Revolution. At two years and counting, what’s the secret of success in negotiating pricing under the new AMNOG legislation? Pharmaceutical Executive Vol. 32, No. 12: 30-33

At two years and counting, what`s the secret of success in negotiating pricing under the new AMNOG legislation? – The introduction in January 2011 of the Act on Reform of the Market for Pharmaceutical Products (AMNOG) has transformed the German pharmaceutical business like no law before, with significant long-term implications for the way companies develop and commercialize their products, not only in Europe (where 19 countries use Germany as the reference point for local pricing) but globally as well. Prior to last year, pricing for new drugs was basically free at time of launch; AMNOG drastically changed the equation by introducing an administratively-complex pricing system based on evidence of a new drug`s additional benefit over established, often generic therapy. Now that we have nearly two years of practical exposure to the law, with more than 30 drugs assessed under the new rules, it`s useful to examine some key precedents that will shape the pricing environment going forward.

Read the whole article for free here (German only).

Hagen, A., Gorenoi, V., Schönermark, M.P. (2010): Specific immunotherapy (SIT) in the treatment of allergic rhinitis. GMS Health Technol Assess 2010; 6:01

Scientific background:
Allergic rhinitis (AR) exhibits a prevalence of approx. 20% in Germany and causes enormous costs in the health care system. Specific immunotherapy (SIT) is considered to be the only potentially causal therapy for AR and mainly administered by two routes, subcutaneous (SCIT) and sublinguale (SLIT). SIT promises a reduction of symptoms and the need for medication in patients with AR.

Read the whole article for free here.

Hagen, A., Gorenoi, V., Schönermark, M.P. (2010): Spezifische Immuntherapie (SIT) zur Behandlung der allergischen Rhinitis.Schriftenreihe HTA des DIMDI, Band 96; 1. Aufl., ISSN: 1864-9645

You can download the whole article for free here (German only).

Gorenoi, V., Schönermark, M.P., Hagen, A. (2010): Prevention of infection after knee arthroplasty. GMS Health Technol Assess 2010; 6:10

Scientific background:
Man-made joints (joint endoprostheses), including knee endoprostheses, are used in some irreversible diseases of the human joints. The implantation of joint endoprostheses (arthroplasty) is associated with an increased risk for infection. To prevent infections, different interventions without and with the use of antibiotics (hygiene procedures and antibiotic prophylaxis) are used. The benefits of these interventions are not clear yet.

Read the whole article for free here.

Gorenoi, V., Schönermark, M.P., Hagen, A. (2010): "Infektionsschutz in der Knieendoprothetik".Schriftenreihe HTA des DIMDI, Band 104; 1. Aufl., ISSN: 1864-9645

You can download the whole article for free here (German only).

Wolter, A.-B., Schönermark, M.P. (2006): Erfolgreiches Arzneimittelmanagement – Strategische Handlungsoptionen aus Sicht der Krankenversicherung. Versicherungswirtschaft, Jg. 61, 06/2006, S. 1003-1004

Read the whole article here (German only).

List of Talks

  • Schönermark, M.P. (2017): Market Access in Germany, World Orphan Drug Congress, Washington, DC und Barcelona
  • Schönermark, M.P. (2016): Market Access in Germany, World Orphan Drug Congress, Barcelona
  • Schönermark, M.P. (2016): Nutzenbewertung von innovativer Medizintechnik, Akademietag der Leopoldina, Hannover
  • Schönermark, M.P. (2015): Das IQTiG – Aufgaben, Ziele, Herausforderungen. BV Managed Care, Berlin
  • Schönermark, M. P. (2013): Die frühe Nutzenbewertung: Wie das Verfahren funktioniert und was Firmen beachten sollten, Bionnale 2013, 7. Mai 2013, Berlin
  • Schönermark, M. P. (2013): Biosimilars im Spannungsfeld zwischen Wettbewerb und Regulierung, Diskussionforum, BMC Kongress 2013, 22./ 23. Januar 2013, Berlin

Clients

  • Alexion Pharmaceuticals
  • Astellas Pharma
  • Bayer Vital
  • Berlin Chemie
  • Bristol Myers Squibb
  • Celgene
  • Destin Arzneimittel
  • Gilead
  • HMNC
  • Laboratoires C.T.R.S.
  • Lilly
  • Lundbeck
  • MerckSerono
  • Mundipharma
  • Novartis
  • Piramal
  • Pfizer
  • Roche Pharma
  • Santen
  • Shionogi & Co.
  • Shire Deutschland
  • United Therapeutics
  • UCB Germany
  • Verband forschender Arzneimittelhersteller

Your Contact Person

Prof. Dr. med. Matthias P. Schönermark, M.D., Ph.D
schoenermark[at]skc-beratung.de